Capital Group International Focus Equity ETF (CGXU)
- Previous Close
26.68 - Open
26.68 - Bid 26.02 x 900
- Ask 27.59 x 1300
- Day's Range
26.67 - 26.91 - 52 Week Range
20.80 - 27.52 - Volume
295,908 - Avg. Volume
409,767 - Net Assets 3.1B
- NAV 26.75
- PE Ratio (TTM) 20.00
- Yield 0.93%
- YTD Daily Total Return 13.24%
- Beta (5Y Monthly) 0.00
- Expense Ratio (net) 0.54%
The fund invests primarily in common stocks of companies domiciled outside the United States, including companies domiciled in emerging markets (but in no fewer than three countries), that the investment adviser believes have the potential for growth. It normally invests at least 80% of its assets in equity securities. The fund is non-diversified.
Capital Group
Fund Family
Foreign Large Growth
Fund Category
3.1B
Net Assets
2022-02-22
Inception Date
Performance Overview: CGXU
View MoreTrailing returns as of 10/11/2024. Category is Foreign Large Growth.
People Also Watch
Holdings: CGXU
View MoreTop 9 Holdings (29.59% of Total Assets)
Sector Weightings
Related ETF News
View MoreResearch Reports: CGXU
View MorePfizer's Diverse Portfolio of Drugs and Vaccines Supports a Wide Moat
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
RatingPrice TargetWhat does Argus have to say about BB?
BLACKBERRY LTD has an Investment Rating of SELL; a target price of $2.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Low; and a Value Subrating of Low.
RatingPrice TargetJohnson & Johnson Earnings: Largely in Line as New Products Ready to Offset Stelara Biosimilars
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.
RatingPrice TargetNew products and M&A drive 2024 growth
Johnson & Johnson is a diversified global healthcare company that develops, manufactures and markets products in two business segments: Innovative Medicine (formerly Pharmaceuticals) and MedTech.
RatingPrice Target